Eli Lilly’s Innovation Statement: Advocating Drug Pricing Reforms

By HEOR Staff Writer

August 18, 2025

Eli Lilly has issued a statement advocating for US drug pricing reforms. It emphasizes maintaining America’s leadership in biopharmaceutical innovation. The Eli Lilly innovation statement highlights a $50 billion US manufacturing investment since 2020. This includes four new sites and opposes tariffs that could disrupt access and raise costs. Lilly stresses balancing affordability with financial viability for R&D.

Key Insights

Investment in Domestic Manufacturing: Lilly’s $50 billion expansion is among the largest recent US pharmaceutical investments. It aims to boost API production and injectable therapy capacity while creating high-skilled jobs.

Strategic Position on Pricing: The company supports a nuanced pricing approach. It warns that US price cuts must sustain innovation funding, possibly requiring adjustments in other markets.

Opposition to Trade Barriers: Lilly opposes pharmaceutical tariffs, arguing they increase costs and harm patient access. Such measures could weaken US competitiveness in drug development.

Partnership Approach: The company advocates for public-private partnerships. It calls for incentives like tax credits to balance innovation with patient access.

Background Context

The US pharmaceutical market has higher drug prices than other nations. This has drawn criticism but also funds global R&D. Drug pricing reform debates have grown, with policies aiming to balance affordability and innovation. Manufacturing reshoring has gained importance post-COVID for supply chain resilience.

Implications

Health Economics Impact: Lilly’s stance highlights global market ties and innovation financing. US price cuts may lead to hikes elsewhere.

Manufacturing Strategy: The $50 billion investment boosts domestic production, improving supply chain resilience for critical medications.

Policy Considerations: The company prefers targeted incentives over tariffs, urging nuanced healthcare industrial policies.

Innovation Sustainability: Balancing affordability with R&D funding remains key for long-term innovation and patient access.

For details, see the Eli Lilly innovation statement here.

Reference url

Recent Posts

FDA Cancer Trial Guidelines: Prioritizing Overall Survival for Patient-Centered Approvals

By João L. Carapinha

October 23, 2025

The FDA cancer trial guidelines from August 2025 emphasize overall survival (OS) as the key endpoint for oncology drug approvals. If you're wondering how these FDA cancer trial guidelines impact patient outcomes in treatment trials, they shift focus from surrogate measures like progression-free s...
Fabhalta Kidney Treatment Shows Promise in Slowing Disease Progression for IgA Nephropathy

By João L. Carapinha

October 21, 2025

Novartis has announced positive final results from the Phase III APPLAUSE-IgAN trial, which demonstrated that Fabhalta kidney treatment (iptacopan) achieved a statistically significant and clinically meaningful slowing of kidney function decline in patients with IgA nephropathy compared to placeb...
Cabotegravir HIV Prevention: First Injectable PrEP Recommended for High-Risk Groups

By HEOR Staff Writer

October 17, 2025

Cabotegravir HIV prevention is now officially recommended in the UK for adults and young people at high risk of HIV who cannot take daily oral PrEP. What makes this approval so significant? For those unable to adhere to daily medication, cabotegravir provides a bi-monthly injectable alternative w...